HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market research developments

This article was originally published in The Rose Sheet

Executive Summary

In a blow to market researcher Information Resources, Inc., Procter & Gamble announced Dec. 13 it will use ACNielsen as its market share data provider, ending a nine-year relationship with IRI. Announcement followed news that IRI plans to cut about 5% of its workforce in the U.S. and Europe through layoffs and elimination of open positions. Move will result in $7.8 mil. pre-tax charge in the fourth quarter, which will cause the company to miss 2002 earnings target, IRI says. Layoffs are intended to reduce costs related to company's retail tracking business and allow for greater investment in opportunities including expanded channel coverage, according to firm. IRI third quarter revenues increased 2% to $140.6 mil., as a 5% decline in retail tracking revenues was offset by an 18% gain in panel and analytic products and services. Net income was $900,000, compared to a $500,000 loss in prior-year period...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010822

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel